Tag: Immunotherapy
Sublingual Immunotherapy Safe, Effective for Treating Toddlers’ Peanut Allergy
Improved outcomes seen with younger age at initiation
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
Anti-PD-L1 agent induces sustained responses seen in about one-third of patients with advanced alveolar soft part sarcoma
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
Progression-free survival and overall survival prolonged with zolbetuximab plus CAPOX versus placebo plus CAPOX
Some Immunosuppressed Do Not Have Anti-Spike Antibodies After COVID-19 Vaccination
IgG anti-spike antibodies undetectable in ~20 percent with immunosuppression who had received three or more COVID-19 vaccines
Most Immunosuppressive Drugs Not Linked to Risk for Cancer
No associations seen for TNF inhibitor, antimetabolite, calcineurin inhibitor, or alkylating agent classes with cancer
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
Significant improvement seen in progression-free survival for combination of nivolumab and ipilimumab
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
Worse OS seen in association with visceral metastases, ECOG performance status ≥1, higher neutrophil/lymphocyte ratio
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
Cancer patients with clinically significant immune-related adverse events had significantly lower tolerant fraction
Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
Risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia elevated, but risks lower in recent years
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy
